Table 2.
Compliance with SLICC 2012 Criteria in the population studied.
| Criteria |
N (%) |
|---|---|
| N Total |
146 |
| Meets SLICC 2012 criteria | 125 (85,62) |
| Acute cutaneous lupus | 45 (30.82) |
| Photosensitive lupus rash | 34/139 (24.46) |
| Lupus malar rash | 19/138 (13.77) |
| Toxic epidermal necrosis | 3/129 (2.33) |
| Subacute cutaneous lupus | 3/134 (2.24) |
| Maculopapular lupus rash | 1/134 (0.75) |
| Chronic cutaneous lupus | 10 (6.85%) |
| Classic discoid rash | 9/143 (6.29) |
| Lupus panniculitis | 1/138 (0.72) |
| Discoid lupus/lichen planus overlap | 1/137 (0.73) |
| Oral or nasal ulcers | 32/135 (23.7) |
| Non-scarring alopecia | 40/137 (29.2) |
| Synovitis | 93/143 (65.03) |
| Serositis | 33 (22.6) |
| Pleural effusion | 22/140 (15.71) |
| Pericardial effusion | 20/140 (14.29) |
| Pleurisy | 8/140 (5.71) |
| Pericardial pain | 7/140 (5.0) |
| Acute pericarditis | 6/141 (4.26) |
| Pleural rub | 5/133 (3.76) |
| Pericardial rub | 5/133 (3.76) |
| Renal | 56/146 (38.35) |
| 24-h urine proteinuria | 49/140 (35.0) |
| Urine protein–to-creatinine ratio | 27/126 (21.4) |
| Red blood cell casts | 18/134 (13.4) |
| Neurological | 23/146 (15.75) |
| Seizures | 9/141 (6.38) |
| Cranial or peripheral neuropathy | 9/134 (6.72) |
| Psychosis | 6/142 (4.23) |
| Acute confusional state | 4 (2.84) |
| Myelitis | 2/141 (1.42) |
| Mononeuritis Multiple | 1/142 (0.70) |
| Hemolytic anemia | 37/142 (26.0) |
| Lymphopenia | 48/146 (32.88) |
| Leukopenia | 35/138 (25.36) |
| Thrombocytopenia | 39/136 (28.6) |
| Immunological criteria | |
| Anti dsDNA | 74/131 (56.49) |
| Anti SM | 47/119 (39.50) |
| Antiphospholipid Antibodies | 44/146 (30.1) |
| LA | 30/101 (29.7) |
| IGG aCL | 16/103 (15.53) |
| IGM aCL | 16/100 (16.0) |
| IGA aCL | 6/46 (13.04) |
| IGM B2GPI | 11/83 (13.25) |
| IGG B2GPI | 10/83 (12.05) |
| Low complement | 100 (68.5) |
| Low C4 | 87/135 (64.44) |
| Low C3 | 86/136 (63.24) |
| Low CH50 | 1/26 (3.85) |
| Positive direct Coombs' test | 28/65 (43.08) |
ANA: Anti-nuclear antibody, anti-dsDNA: anti-double-stranded deoxyribonucleic acid, anti SM: anti-Smith, aCL. Anti-Cardiolipin, B2GPI: anti-β2-glycoprotein I, CH50: total complement activity, LA: Lupus anticoagulant, SLICC: Systemic Lupus International Collaborating Clinics.